KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.

Xue-Feng Kan, Bin Liang, Xiao-Lin Zhang, Lei Yu, Yao-Chang Luo, Shi Zhou, Rui-Bao Liu, Guo-Hui Xu, Hai-Liang Li, Zheng-Yin Liao, Hua Xiang, Wei Lu, Lin-Feng Xu, Yi-Long Ma, Xiang-Wen Xia, Kun Qian, Xiang-Jun Dong, Fu Xiong, Song-Lin Song, Chang Zhao, Ming Huang, Chuan-Sheng Zheng

BMC Med 23(1) 313

PMID40437469
PMCIDPMC12121135
DOI10.1186/s12916-025-04159-y
发表日期2025-05-28
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
KM panel re-extraction failed
摘要

摘要

BACKGROUND: This study aimed to assess the efficacy and safety of transarterial chemoembolization (TACE) in combination with apatinib (TACE-apatinib) for patients with unresectable hepatocellular carcinoma (HCC). METHODS: This study was a multicenter, randomized, open-label, prospective, phase III trial. Patients with unresectable HCC were randomly assigned in a 1:1 ratio to receive either TACE-apatinib or TACE-alone treatment. Patients in the TACE-apatinib group began with a dosage of 500 mg/day of oral apatinib administered 4 days after the first TACE. The primary endpoint of this study was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to untreatable (unTACEable) progression (TTUP), and safety assessment. RESULTS: From November 1, 2018 to November 18, 2021, a total of 196 patients were randomly assigned to either the TACE-apatinib (n = 86) or TACE-alone (n = 92) group. The median PFS in the TACE-apatinib group was significantly longer than that of in the TACE-alone group (6.1 months vs. 3.4 months, p < 0.0001). The median OS was significantly prolonged in the TACE-apatinib group compared to the TACE-alone group (28.9 months vs. 24.0 months, p = 0.0005). The median TTUP in the TACE-apatinib group was 26.8 months, which was significantly longer than that of 20.1 months in the TACE-alone group (p = 0.0003). A significantly higher ORR and DCR were observed in the TACE-apatinib group compared to the TACE-alone group (ORR: 58.1% vs. 31.5%, p < 0.001; DCR: 87.2% vs. 69.6%, p = 0.004). Most of the treatment-related adverse events were grades 1-2, and no treatment-related deaths were observed. CONCLUSIONS: Apatinib significantly improved the treatment effects of TACE for patients with unresectable HCC. TACE-apatinib could serve as a promising treatment option for this patient population, offering notable survival benefits while maintaining an acceptable safety profile. TRIAL REGISTRATION: Chinese Clinical Trial Register, No. ChiCTR1800018621.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Kaplan–Meier curve ( A ) and forest plot ( B ) of progression-free survival for patients in the TACE-apatinib group and TACE-alone group. TACE, transarterial chemoembolization; TACE-apatinib, TACE combined with apatinib

A

progression-free survival

Fig. 2 · Panel A

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
No curves extracted
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient flow chart (consort diagram). TACE, transarterial chemoembolization; FAS, full analysis set
非 KM Figure
Fig. 3Kaplan–Meier curve ( A ) and forest plot ( B ) of overall survival for patients in the TACE-apatinib group and TACE-alone group. TACE, transarterial chemoembolization; TACE-apatinib, TACE combined with apatinib
非 KM Figure